Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$8.86
-0.20 (-2.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-31.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.3B
P/E
295.3x
↑EV/EBITDA
70.5x
↑ROE
0.4%
↑Gross Margin
65.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.0%
FCF CAGR
—
FCF margin
-18.1%
FCF / Net income
-5.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $404.7M · net income $14.6M · FCF $-73.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $404.7M | $404.7M | $416.5M | $476.6M | $734.5M |
| Net Income | $14.6M | $14.6M | $-68.9M | $102.9M | $204.7M |
| EBITDA | $60.1M | $60.1M | $72.0M | $7.7M | $82.8M |
| EPS | 0.03 | 0.03 | -0.14 | 0.21 | 0.43 |
| Gross Margin | 65.1% | 65.1% | 66.3% | 70.4% | 76.6% |
| Operating Margin | -2.2% | -2.2% | 6.0% | -8.6% | 4.8% |
| Net Margin | 3.6% | 3.6% | -16.5% | 21.6% | 27.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | — | — | — |
| Current Ratio | 20.09 | 20.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-73.2M | $-73.2M | $34.8M | $-31.7M | $67.1M |
| Returns | |||||
| ROE | 0.4% | 0.4% | -2.1% | 3.0% | 6.1% |
| Valuation | |||||
| P/E | 295.33 | 295.33 | — | 49.24 | 28.12 |
| EV/EBITDA | 70.48 | 70.48 | 44.69 | 642.25 | 66.82 |
| P/B | 1.28 | 1.28 | 0.98 | 1.47 | 1.71 |
| Growth & Yield | |||||
| Revenue Growth | -2.8% | -2.8% | -12.6% | -35.1% | — |
| EPS Growth | 121.4% | 121.4% | -166.7% | -51.2% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
197.0%
EPS terminal req.
$0.79
Spread vs growth
-75.6%
5Y implied EPS CAGR
99.6%
EPS terminal req.
$0.95
Spread vs growth
21.8%
10Y implied EPS CAGR
48.2%
EPS terminal req.
$1.53
Spread vs growth
73.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.14 → 0.03
Residual
-7.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.